Jonathan W Friedberg

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. doi request reprint Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Ave, Box 704, Rochester, NY, 14642, USA
    J Clin Oncol 26:204-10. 2008
  2. doi request reprint Relapsed/refractory diffuse large B-cell lymphoma
    Jonathan W Friedberg
    James P Wilmot Cancer Center and University of Rochester, Rochester, NY 14642, USA
    Hematology Am Soc Hematol Educ Program 2011:498-505. 2011
  3. pmc Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study
    Jonathan W Friedberg
    University of Rochester, 601 Elmwood Ave, Box 704, Rochester, NY 14642, USA
    J Clin Oncol 30:3368-75. 2012
  4. ncbi request reprint Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
    Leuk Res 28:139-47. 2004
  5. pmc The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, Rochester, NYm, USA
    Blood 117:2807-12. 2011
  6. ncbi request reprint Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, Box 704, Room 1 4118C, NY 14642, USA
    Curr Treat Options Oncol 7:276-84. 2006
  7. pmc Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, NY 14642, USA
    Blood 115:2578-85. 2010
  8. pmc Treatment of follicular non-Hodgkin's lymphoma: the old and the new
    Jonathan W Friedberg
    University of Rochester, Rochester, NY 14612, USA
    Semin Hematol 45:S2-6. 2008
  9. pmc Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA
    Br J Haematol 146:282-91. 2009
  10. pmc Diffuse large B-cell lymphoma
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, Box 704, Room 1 4118C, Rochester, NY 14642, USA
    Hematol Oncol Clin North Am 22:941-52, ix. 2008

Research Grants

  1. Monoclonal Antibody Therapy for Follicular Lymphoma
    Jonathan Friedberg; Fiscal Year: 2007

Collaborators

Detail Information

Publications54

  1. doi request reprint Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Ave, Box 704, Rochester, NY, 14642, USA
    J Clin Oncol 26:204-10. 2008
    ..This phase II multicenter study evaluated the efficacy and toxicity of bendamustine in patients with B-cell non-Hodgkin's lymphoma (NHL) refractory to rituximab...
  2. doi request reprint Relapsed/refractory diffuse large B-cell lymphoma
    Jonathan W Friedberg
    James P Wilmot Cancer Center and University of Rochester, Rochester, NY 14642, USA
    Hematology Am Soc Hematol Educ Program 2011:498-505. 2011
    ..The large group of patients not eligible for ASCT have incurable disease and should be referred for clinical trials of rationally targeted agents...
  3. pmc Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study
    Jonathan W Friedberg
    University of Rochester, 601 Elmwood Ave, Box 704, Rochester, NY 14642, USA
    J Clin Oncol 30:3368-75. 2012
    ..Diverse treatment approaches are used despite guidelines that recommend radiation therapy (XRT)...
  4. ncbi request reprint Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
    Leuk Res 28:139-47. 2004
    ..Larger studies are indicated to determine optimal timing of STAT1 assessment, and if changes in STAT1 represent an in vivo indicator of response to purine analog therapy...
  5. pmc The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, Rochester, NYm, USA
    Blood 117:2807-12. 2011
    ..On the basis of these promising results, the US cooperative groups have initiated randomized trials to evaluate this regimen in follicular and mantle cell lymphoma. This trial was registered at www.clinicaltrials.gov as #NCT00547534...
  6. ncbi request reprint Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, Box 704, Room 1 4118C, NY 14642, USA
    Curr Treat Options Oncol 7:276-84. 2006
    ..Until such trials are mature, we do not recommend using these agents in combination outside of the research setting...
  7. pmc Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, NY 14642, USA
    Blood 115:2578-85. 2010
    ..2 months. Disrupting BCR-induced signaling by inhibiting Syk represents a novel and active therapeutic approach for NHL and SLL/CLL. This trial was registered at www.clinicaltrials.gov as #NCT00446095...
  8. pmc Treatment of follicular non-Hodgkin's lymphoma: the old and the new
    Jonathan W Friedberg
    University of Rochester, Rochester, NY 14612, USA
    Semin Hematol 45:S2-6. 2008
    ..In addition, several novel agents show encouraging activity in follicular lymphoma, including bendamustine, lenalidomide, bortezomib, and other proteasome inhibitors, and BCL2 inhibitors...
  9. pmc Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA
    Br J Haematol 146:282-91. 2009
    ..This study is the first to histologically confirm perturbation of the local immune microenvironment following systemic biological therapy of follicular lymphoma...
  10. pmc Diffuse large B-cell lymphoma
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, Box 704, Room 1 4118C, Rochester, NY 14642, USA
    Hematol Oncol Clin North Am 22:941-52, ix. 2008
    ....
  11. pmc New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice
    Jonathan W Friedberg
    University of Rochester Medical Center, Rochester, New York 14642, USA
    Clin Cancer Res 17:6112-7. 2011
    ..Results of ongoing studies suggest that in the near future, we will be able to use gene expression profiling, or an accurate surrogate, to define the best therapeutic approach for individual patients with DLBCL...
  12. ncbi request reprint Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA
    Blood 105:489-95. 2005
    ..CpG treatment resulted in no significant toxicity, providing rationale for further testing of this exciting combination immunotherapy approach to NHL...
  13. ncbi request reprint Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma
    Jonathan W Friedberg
    Lymphoma Program, James P Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA
    Expert Rev Anticancer Ther 4:18-26. 2004
    ..Studies are also addressing the role of iodine-131 tositumomab as a component of initial therapy for indolent non-Hodgkin's lymphoma and in additional histologies of non-Hodgkin's lymphoma...
  14. ncbi request reprint FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
    Leuk Lymphoma 45:85-92. 2004
    ..However, more patients have persistently positive PET at the end of chemotherapy compared with gallium (P = 0.04), although only half of these patients have relapsed...
  15. ncbi request reprint Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, PO Box 704, Rochester, NY 14642, USA
    Cancer 98:978-82. 2003
    ..The authors conducted a trial substituting this drug for dacarbazine in the standard regimen to form ABVG (doxorubicin, bleomycin, vinblastine, gemcitabine) for patients with newly diagnosed, high-risk HD...
  16. ncbi request reprint Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma
    J W Friedberg
    Lymphoma Program, James P Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA
    Bone Marrow Transplant 32:681-6. 2003
    ..The paucity of PCR-informative patients, possibly related to in vivo rituximab therapy, limited the utility of minimal residual disease as a surrogate marker of clinical outcome...
  17. doi request reprint Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era
    Tithi Biswas
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Int J Radiat Oncol Biol Phys 77:79-85. 2010
    ..We evaluated the role of involved field radiation therapy (IFRT) post-ASCT for patients initially induced with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) or, more recently, rituximab-CHOP (R-CHOP)...
  18. pmc Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era
    Sarah F Keller
    James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
    Biol Blood Marrow Transplant 18:640-7. 2012
    ..Our results emphasize the importance of long-term follow-up for both toxicity and recurrence, and have important implications in defining success of posttransplantation maintenance strategies...
  19. pmc High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era
    Makiko Ban-Hoefen
    James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA
    Leuk Lymphoma 53:830-5. 2012
    ..However, patients exposed to rituximab pre-transformation appear to have inferior HD-ASCT outcomes, and thus may benefit from novel conditioning and maintenance regimens in the setting of HD-ASCT...
  20. ncbi request reprint Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma
    Julia Schaefer-Cutillo
    James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York 14642, USA
    Oncology (Williston Park) 21:203-12; discussion 214, 217, 221. 2007
    ....
  21. doi request reprint Non-myeloablative radioimmunotherapy for non-Hodgkin's lymphoma
    Julia Schaefer-Cutillo
    Lymphoma Program, James P Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA
    Semin Hematol 45:110-7. 2008
    ....
  22. pmc Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion
    Paul M Barr
    James P Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA
    Clin Immunol 142:237-42. 2012
    ....
  23. doi request reprint Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma
    Alison R Walker
    University of Rochester, Hematology Oncology, Rochester, New York 14642, USA alison
    Cancer Invest 26:431-3. 2008
    ..The patient was started on monthly intravenous immunoglobulin treatments with complete resolution of her symptoms...
  24. doi request reprint Salvage therapy in Hodgkin's lymphoma
    Jason H Mendler
    James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
    Oncologist 14:425-32. 2009
    ..We conclude by providing our approach to these patients, with the hope that this will serve as a framework for the practicing oncologist...
  25. pmc A case-control study of ultraviolet radiation exposure, vitamin D, and lymphoma risk in adults
    Jennifer L Kelly
    Department of Community and Preventive Medicine, University of Rochester, 601 Elmwood Ave, Box 644, Rochester, NY 14642, USA
    Cancer Causes Control 21:1265-75. 2010
    ....
  26. pmc Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab
    Shannon P Hilchey
    James P Wilmot Cancer Center, Aab Institute of Biomedical Sciences, and Department of Microbiology and Immunology, School of Medicine and Dentistry, University of Rochester, NY 14642, USA
    Blood 113:3809-12. 2009
    ..Our data thus provide "proof of principle" for the ability of passive immunotherapy with rituximab to elicit an active FL-specific cellular response...
  27. doi request reprint A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection
    Gordon L Phillips
    Hematology Oncology, University of Rochester Medical Center, James P Wilmot Cancer Center, Strong Memorial Hospital, Rochester, New York 14642, USA
    Biol Blood Marrow Transplant 17:1033-42. 2011
    ..A Phase II trial is planned...
  28. doi request reprint Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy?
    David W Dougherty
    James P Wilmot Cancer Center, Division of Hematology Oncology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
    Curr Hematol Malig Rep 5:148-56. 2010
    ..This article briefly reviews current primary treatment strategies for HL and examines the existing data for both new cytotoxic agents and other selected novel agents in the treatment of HL...
  29. ncbi request reprint Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database
    Makiko Ban-Hoefen
    Department of Hematology and Oncology, James P Wilmot Cancer Center, University of Rochester, Rochester, NY, USA
    Br J Haematol 163:487-95. 2013
    ..Younger patients who were not exposed to chemotherapy prior to HT experienced a prolonged survival even without transplantation. This study serves as a benchmark for future trials of novel approaches for HT in the Rituximab era...
  30. ncbi request reprint B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny
    Jennifer H Anolik
    Department of Medicine, Division of Clinical Immunology and Rheumatology, James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Clin Immunol 122:139-45. 2007
    ..0001). Expansion of functionally immature B cells and decreased memory B cells may contribute to an immunodeficient state in patients recovering from rituximab mediated B cell depletion, particularly with repeated treatment...
  31. ncbi request reprint Beyond rituximab: the future of monoclonal antibodies in B-cell non-Hodgkin lymphoma
    Manzurul A Sikder
    James P Wilmot Cancer Center, Division of Hematology Oncology, University of Rochester, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
    Curr Oncol Rep 10:420-6. 2008
    ..Approval of such antibodies by regulatory committees and their eventual integration into clinical practice will likely depend on positive results from randomized trials...
  32. pmc Novel agents in mantle cell lymphoma
    Marcus S Noel
    University of Rochester Medical Center, James P Wilmot Cancer Center, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
    Best Pract Res Clin Haematol 25:191-200. 2012
    ..With further understanding of cellular signaling, the armamentarium of treatment options will be enhanced, with the hope of improving the prognosis of this disease...
  33. pmc Follicular lymphoma in the United States: first report of the national LymphoCare study
    Jonathan W Friedberg
    Wilmot Cancer Center, University of Rochester, Rochester, NY, USA
    J Clin Oncol 27:1202-8. 2009
    ..Optimal therapy of follicular lymphoma (FL) is not defined. We analyzed a large prospective cohort study to identify current demographics and patterns of care of FL in the United States...
  34. pmc PCR assays detect B-lymphocyte clonality in formalin-fixed, paraffin-embedded specimens of classical hodgkin lymphoma without microdissection
    W Richard Burack
    Department of Pathology, James P Wilmot Cancer Center, University of Rochester School of Medicine, NY, USA
    Am J Clin Pathol 134:104-11. 2010
    ..These data and 2 representative cases demonstrate that PCR-based B-cell clonality assays have usefulness when the histologic differential diagnosis of an FFPE specimen includes classic HL...
  35. doi request reprint Patterns and timing of initial relapse in patients subsequently undergoing transplantation for Hodgkin's lymphoma
    Sughosh Dhakal
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Int J Radiat Oncol Biol Phys 75:188-92. 2009
    ....
  36. doi request reprint Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma
    Manzurul A Sikder
    James P Wilmot Cancer Center, Division of Hematology Oncology, University of Rochester, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
    Curr Hematol Malig Rep 3:187-93. 2008
    ..Approval of such antibodies by regulatory committees and their eventual integration into clinical practice will likely depend on positive results from randomized trials...
  37. ncbi request reprint Diffuse large B-cell NHL
    Jonathan W Friedberg
    University of Rochester Medical Center, James P Wilmot Cancer Center, Lymphoma Program 601 Elmwood Avenue, Box 704 Rochester, NY 14642, USA
    Cancer Treat Res 131:121-40. 2006
  38. pmc Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens
    Jennifer L Kelly
    James P Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA
    Clin Lymphoma Myeloma 9:307-10. 2009
    ....
  39. pmc Vitamin D and non-Hodgkin lymphoma risk in adults: a review
    Jennifer L Kelly
    Department of Community and Preventive Medicine, University of Rochester, Rochester, NY 14642, USA
    Cancer Invest 27:942-51. 2009
    ..This review provides a comprehensive discussion of the current epidemiologic evidence with regard to the investigation of an association between vitamin D status and NHL risk...
  40. ncbi request reprint PET scans in the staging of lymphoma: current status
    Jonathan W Friedberg
    Lymphoma Program, James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
    Oncologist 8:438-47. 2003
    ..Clearly, additional studies, including prospective blinded trials and cost-effectiveness analyses, are warranted to determine which subsets of patients with lymphoma ultimately will benefit from this modality...
  41. ncbi request reprint Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report
    G L Phillips
    The James P Wilmot Cancer Center, BMT Program, Rochester, NY 14642, USA
    Semin Oncol 31:59-61. 2004
    ..Patient entry at the starting dose (ie, HD-MEL 140 mg/m2) has been completed without the development of severe regimen-related toxicities. This trial is ongoing...
  42. ncbi request reprint Developing new monoclonal antibodies for aggressive lymphoma: a challenging road in the rituximab era
    Jonathan W Friedberg
    Clin Cancer Res 10:5297-8. 2004
  43. ncbi request reprint Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma
    Jonathan W Friedberg
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Br J Haematol 117:828-34. 2002
    ..Further studies of this rational combination are warranted and ongoing...
  44. ncbi request reprint Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 23:2208-14. 2005
    ..We report the incidence and outcome of solid tumors at 10-year follow-up in a large cohort of uniformly treated patients who underwent ABMT for non-Hodgkin's lymphoma (NHL)...
  45. ncbi request reprint Rituximab for early-stage diffuse large-B-cell lymphoma
    Jonathan W Friedberg
    Lancet Oncol 7:357-9. 2006
  46. pmc Monoclonal antibodies in lymphoma: the first decade
    Brian K Link
    Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA
    Semin Hematol 45:71-4. 2008
    ..Finally, possible future developments in the field will be proposed, including the use of monoclonal antibodies in ablative transplantation and in the treatment of leukemias...
  47. ncbi request reprint Combination treatment approaches and novel therapies for lymphoma
    John P Leonard
    Clin Adv Hematol Oncol 5:4-20; quiz 1 p following 20. 2007
  48. doi request reprint Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma
    Jonathan W Friedberg
    Haematologica 93:336-8. 2008
  49. ncbi request reprint Potential long-term toxicities should influence the choice of therapy for indolent non-Hodgkin's lymphoma
    Jonathan W Friedberg
    Haematologica 91:1453-5. 2006
  50. ncbi request reprint Breast lymphoma associated with breast implants: two case-reports and a review of the literature
    Guylaine Gaudet
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Leuk Lymphoma 43:115-9. 2002
    ..We herein report two unusual cases of anaplastic large cell lymphoma of T-cell phenotype developing in the breasts of women who had received breast implants...
  51. ncbi request reprint Radioimmunotherapy for non-Hodgkin's lymphoma
    Jonathan W Friedberg
    Clin Cancer Res 10:7789-91. 2004
  52. ncbi request reprint Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors
    Andrea K Ng
    Department of Radiation Oncology and the Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Blood 100:1989-96. 2002
    ..Our analysis suggests that the risk may be reduced with smaller radiation fields, as are used in current trials of abbreviated chemotherapy and limited-field radiation therapy...
  53. pmc Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network
    Ann S LaCasce
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 26:5107-12. 2008
    ..We sought to estimate the impact of expert review in the modern era by comparing final pathologic diagnoses at five comprehensive cancer centers with diagnoses assigned at referring centers...
  54. ncbi request reprint Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Leuk Lymphoma 45:315-20. 2004
    ..003). Outcomes of autologous BMT in patients with disseminated marginal zone NHL are similar to those in follicular NHL, and suggest that certain patients may experience prolonged disease-free survival...

Research Grants1

  1. Monoclonal Antibody Therapy for Follicular Lymphoma
    Jonathan Friedberg; Fiscal Year: 2007
    ..abstract_text> ..